Order in the chaos
Decks are written to persuade. The data was written to record. I work from the record.
One mind and a fleet of agents, pointed at the whole published literature -- and at your question. I settle a noisy system into the few facts your decision rests on, trace each to its source, and tell you which way they point. No predictions -- just the record, read until the gamble’s gone.
25
Years in biotech
$1.2B
Commercial franchise
50+
Deals evaluated
The method
Hand me the pile. I hand back the verdict.
You bring the documents and the question. I scope what you actually need, run it through an engine that verifies every claim against the primary source, and hand back what holds -- dated before the readout, defensible line by line.
01
Scope the need
I start with the decision you are actually making -- a call, a meeting, your question in your own words -- not a generic checklist. I set the depth here, and name it: a fast pass or a deep read. A fast pass clears twenty thousand pages -- a data drop in the night, read and back to you before the opening bell. A deep read takes weeks.
So the read is aimed at what you need to know, and you know exactly what you are buying.
02
Hand me the pile
Your documents, your data room, your question -- in whatever shape they are in. I ingest it and wire it to the live primary record: filings, trials, patents, labels, the literature.
So your private pile and the public record sit in one view -- and the cross-domain landmine surfaces before you wire.
03
The engine verifies
I trace every figure to its source -- verbatim line, durable id, timestamp. A model of a different lineage audits each claim and can only veto it. I date every forward call before the readout.
So every digit is re-checkable, the weak claim dies in private -- not in your investment committee -- and the track record is auditable, not asserted.
04
The verdict
I read every gate myself and hand back the handful of facts your decision rests on, with the logic that connects them -- in whatever form the decision needs.
So you hold a document you can carry into a committee and defend line by line.
The FDA's 2025 guidance on AI in regulatory work now expects exactly this provenance by construction -- so the output meets a standard that turns ungrounded AI away.
How the engine worksThe proof is on the page
Three calls where the source said what the story didn't.
STAT3 · ulcerative colitis
Abivax (ABVX)
Two Phase 3 inductions hit. A $9.3B valuation now rests on a single maintenance readout -- and the report names exactly which number to watch.
AAV gene therapy · Rett syndrome
Neurogene (NGNE)
A pediatric patient died of HLH two weeks after the high dose; the cohort was discontinued. The kind of fact a pitch deck omits and a primary-source audit does not.
gamma-secretase inhibitor · desmoid tumor
Immunome (IMNM)
Phase 3 hazard ratio 0.16; NDA filed. A clean win, read against the published record rather than the company narrative.
And I keep score in public: seven oncology readouts called before the data, then graded against what printed -- the hits and the misses. See the calibration ->
What I can be pointed at
One engine. Every gate of the drug lifecycle.
The same discipline answers the question that matters at each gate. I have stood at every one of these gates for twenty-five years -- the breadth is earned, not claimed.
Who it is for
Two sides of the same table.
For capital
Know which medicines work, before you wire.
Diligence that reads an asset against the published record, not the pitch deck.
- Diligence reads -- every figure traced to the filing, trial, or paper that backs it
- Mechanism and R&D audits that test the science behind the story
- Reads on what the next data readout turns on, mapped to the published record behind it
For founders
Make a real medicine legible to capital.
A clear case that lets investors underwrite a sound asset.
- Grants -- SBIR and beyond, written fast and managed from draft to award
- Target Product Profiles and the regulatory package, built from your own data
- Freedom-to-operate (light), whitespace mapping, and diligence-ready data rooms
One engine sits behind both doors: a 25-year operator, an expert network on call, and AI agents reading the published record. Days, not months -- and every claim traced to its source.
Who stands behind it
BigBio is Christopher Davis.
I have worked every gate the grid above names: bench discovery, diagnostics, a $1.2B commercial franchise, GxP manufacturing, and the investor table. "Point me at anything" is earned at each one, not asserted.
- NIBRR&D / HTS · 6M compounds screened
- MetamarkDiagnostics · ProMark, CLIA/CAP
- Shire$1.2B GI franchise · regulatory ops
- MangoFounder/CEO · zero to market: M6 90-min sterility test (vs 14-day standard), ~50 people, J&J partnership, revenue
- Mass Medical Angels50+ deals reviewed · due diligence
Raised off-grid in a log cabin outside Anahim Lake, British Columbia -- no electricity, no running water -- now working at the bleeding edge of compute in Boston.
The full record ->Latest: From pilot to protagonist ->
See the work, then point me at yours.
Independent reads on the deal you’re weighing or the asset you’re building -- every claim traced to its source, on a deadline.
The front door is the Verified Read: one asset, fixed scope, about ten business days. When the question is bigger than one asset, bespoke diligence is scoped to it.